United Therapeutics Corporation (UTHR)

Market Cap	20.90B +27.2%
Revenue (ttm)	3.13B +13.5%
Net Income	1.27B +14.5%
EPS	26.38 +16.1%
Shares Out	43.06M
PE Ratio	18.40
Forward PE	17.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	297,122
Open	483.81
Previous Close	478.93
Day's Range	481.95 - 489.50
52-Week Range	266.98 - 519.99
Beta	0.86
Analysts	Buy
Price Target	498.83 (+2.78%)
Earnings Date	Feb 25, 2026

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 1,305
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Analyst Summary

According to 12 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $498.83, which is an increase of 2.78% from the latest price.

Price Target

$498.83

(2.78% upside)

Analyst Consensus: Buy